Literature DB >> 2183734

Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy.

W J Johnson1, R A Kyle, A A Pineda, P C O'Brien, K E Holley.   

Abstract

The aims of this study were to examine in a prospective, randomized trial the efficacy of plasmapheresis in preventing irreversible renal failure in patients with multiple myeloma and to study the renal biopsy tissues from such patients. Twenty-one patients with active myeloma and progressive renal failure were randomized to one of two groups: group 1, forced diuresis and chemotherapy (10 patients), and group 2, forced diuresis, chemotherapy, and plasmapheresis (11 patients). Plasmapheresis and chemotherapy lowered the serum myeloma protein value much more rapidly than chemotherapy alone. Of 5 patients who were oliguric and undergoing dialysis at presentation, only 3 who were treated by plasmapheresis recovered. Of 16 polyuric patients, 5 in group 1 and 7 in group 2 showed improvement in renal function. The main factor that determined irreversibility of renal failure was the severity of myeloma cast formation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2183734

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  28 in total

1.  Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.

Authors:  Colin A Hutchison; Paul Cockwell; Stephanie Stringer; Arthur Bradwell; Mark Cook; Morie A Gertz; Angela Dispenzieri; Jeffrey L Winters; Shaji Kumar; S Vincent Rajkumar; Robert A Kyle; Nelson Leung
Journal:  J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 10.121

Review 2.  Myeloma light chain cast nephropathy, a review.

Authors:  Insara Jaffer Sathick; Maria Eleni Drosou; Nelson Leung
Journal:  J Nephrol       Date:  2018-05-05       Impact factor: 3.902

Review 3.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

Review 4.  Onco-nephrology: AKI in the cancer patient.

Authors:  Albert Q Lam; Benjamin D Humphreys
Journal:  Clin J Am Soc Nephrol       Date:  2012-08-09       Impact factor: 8.237

Review 5.  Novel approaches for reducing free light chains in patients with myeloma kidney.

Authors:  Colin A Hutchison; Joan Bladé; Paul Cockwell; Mark Cook; Mark Drayson; Jean-Paul Fermand; Efstathios Kastritis; Robert Kyle; Nelson Leung; Sonia Pasquali; Christopher Winearls
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

6.  Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases.

Authors:  Nelson Leung; Morie Gertz; Robert A Kyle; Fernando C Fervenza; Maria V Irazabal; Alfonso Eirin; Shaji Kumar; Stephen S Cha; S Vincent Rajkumar; Martha Q Lacy; Steve R Zeldenrust; Francis K Buadi; Suzanne R Hayman; Samih H Nasr; Sanjeev Sethi; Marina Ramirez-Alvarado; Thomas E Witzig; Sandra M Herrmann; Angela Dispenzieri
Journal:  Clin J Am Soc Nephrol       Date:  2012-09-27       Impact factor: 8.237

7.  Determination of intrarenal resistance index (RI) in patients with multiple myeloma.

Authors:  U Schiemann; H C Kaiser; M Götzberger; R Schmidmaier; F Bantle; C Straka
Journal:  Eur J Med Res       Date:  2010-05-18       Impact factor: 2.175

Review 8.  Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach.

Authors:  Sanjeev Baweja; Kate Wiggins; Darren Lee; Susan Blair; Margaret Fraenkel; Lawrence P McMahon
Journal:  J Artif Organs       Date:  2010-12-10       Impact factor: 1.731

Review 9.  Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.

Authors:  P Fabbrini; K Finkel; M Gallieni; G Capasso; M Cavo; A Santoro; S Pasquali
Journal:  J Nephrol       Date:  2016-10-18       Impact factor: 3.902

10.  State-of-the-Art Management of Complications of Myeloma and Its Treatment.

Authors:  Monique A Hartley-Brown; Daniel M Sullivan; Rachid Baz
Journal:  Adv Hematol       Date:  2010-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.